All In Biotech

NDA 020392 · Mylan

Cystagon

Cysteamine Bitartrate · Oral

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jun 6, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Aug 15, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

33

8 Phase 3, 2 recruiting

FAERS reports

350

237 serious, 34 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 16, 2021.

INDICATIONS AND USAGE CYSTAGON ® is indicated for the management of nephropathic cystinosis in children and adults.

Mechanism: Mechanism of Action Cystinosis is an autosomal recessive inborn error of metabolism in which the transport of cystine out of lysosomes is abnormal; in the nephropathic form, accumulation of cystine and formation of crystals damage various organs, especially the kidney, leading to renal tubular Fanconi Syndrome and progressive glomerular failure, with end stage renal failure by the end of the first decade of life. In four studies of cystinosis patients before cysteamine was available, renal death (need for transplant or dialysis) occurred at median age of less than 10 years. Patients with...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 15, 1994 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • CYSTAGON · CYSTEAMINE BITARTRATE EQ 50MG BASE · CAPSULE, ORAL · Prescription
  • CYSTAGON · CYSTEAMINE BITARTRATE EQ 150MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cysteamine Bitartrate" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting38
  • diarrhoea22
  • nausea21
  • off label use21
  • eye irritation17
  • abdominal pain15
  • treatment noncompliance15
  • eye pain14
  • headache14
  • pneumonia12
  • abdominal pain upper11
  • decreased appetite11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
20052
20064
20076
20087
20092
20107
20117
20127
20131
201426
201511
201610
201724
201826
201924
202026
202117
202242
202333
202429
202522
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cystagon (Cysteamine Bitartrate)

2024 spending

$58K

Beneficiaries

15

119 claims

Per beneficiary

$3,894

$0.83 per unit

View as table
YearSpending
2020$65,489
2021$55,267
2022$60,165
2023$75,219
2024$58,406

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Mylan

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.